Company Overview and News
begin 644 global91418.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;[email protected]#DO5'EP92]84F5F+U=;,2 R(#%=/CYS=')E86T-"FC>8F)[email protected] M8F!J 1(,?D""\0"08$L%$AQ20((+)*%N )(( Q)\1X"$U#[email protected](>0()[email protected] M'DAO&I!0Z 81KD!"?B,#$R/#3) $ R,-B?^,=]X"[email protected] -W4,[email protected]*96YD
Wall Street is seemingly beside itself these days as the broader market makes new highs. But if you’re of the mind that investors are due for an unpleasant and volatile wake-up call, one clever partial hedge or portfolio diversifier is a pair of bullish options spreads on down, but not out financials CBOE Global Markets (NASDAQ:CBOE) and Virtu Financial (NASDAQ:VIRT).
Cboe Global Markets, Inc.’s (CBOE - Free Report) second-quarter 2018 adjusted earnings of $1.05 per share beat the Zacks Consensus Estimate of $1.03 by 1.9%. Moreover, the bottom line improved nearly 20.7% year over year.
CBOE MKGAF 7018 CME MKGAY MKTX BGSF
The following slide deck was published by CBOE Holdings in conjunction with their 2018 Q2 earnings call.
CBOE Holdings (CBOE - Free Report) just came out with quarterly earnings of $1.05 per share, beating the Zacks Consensus Estimate of $1.03 per share. This compares to earnings of $0.87 per share a year ago. These figures are adjusted for non-recurring items.
cboe_Current_Folio_10Q Table of Contents
2018-07-28 seekingalpha - 3
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
YUM CAT BNPQY ILMN PGNX SLGL RGR 1128 ZNGA MVBFP MVBFO 1928 AKAM LNG FTSI JACK LKQ RECN SPA GPRO BNPZY BABA ITW NEXT SPG UTHR FCAU MGM FB FIT CAAP FRC TM CGNX DVN MDCO ATVI SJMHY MLCO PSBQ AGN AAPL RIG BIDU STRA LUV CBS WYNN CEPU HUD AWR WYNMF BNPQF HMC 0880 EOG BHI KHC INBK CCOI CAKE WYNMY CBOE HAFC CQP TWX PXD UAL RMD PSBH FUV DOV VLKAY SMG SQ BY TTWO AAL IDXX HOG CMG BRK.A BP MSBI FRT SJMHF PFE PG STX CHE WGO CCBG COO MYL UCFC CPLA QCRH GM RMD PII DAL MSCI LFUS OSS F XPO CMCSA SCHYF P COG TRTN DWDP MFSF MVBF 506186 GLXYENT BMRC TXT TELL SCHYY
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET